Atibuclimab not checked
Implicit Bioscience · IC14 · Anti-CD14
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- Tested for
- Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome, Acute Lung Injury, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
- Main trialPhase 2
- “Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.”In the company’s words, NCT06513949 on ClinicalTrials.gov
- Other names
- IC14 · Anti-CD14 · monoclonal antibody against CD14 · anti-CD14 monoclonal antibody
Other drugs for Acute Respiratory Distress Syndrome
- APC-0101Aerogen Pharma Limited · Phase 3
- TozorakimabAstraZeneca · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- LEAF-4L6715LEAF4Life, Inc. · Phase 3
- STSA-1002Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
Coming up1
- 1 Mar 2029Phase 2 trial completes · ClinicalTrials.gov
Changes4
Last 90 days- 13 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06556810
- 13 NovCompletion date moved: 2026-04-30 to 2026-08-30 · ClinicalTrials.gov NCT06556810
- 13 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT06678074
- 13 NovCompletion date moved: 2026-06-01 to 2026-08-01 · ClinicalTrials.gov NCT06678074
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 1 Mar 2029 | Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients | |
| Phase 2Withdrawn | Jan 2020 | IC14 in Adult Patients With Dengue Fever | |
| Phase 2Withdrawn | Jun 2020 | A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome | |
| Phase 2Withdrawn | 12 Apr 2021 | IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) | |
| Phase 2Withdrawn | 15 May 2023 | IC14 for Treatment of Amyotrophic Lateral Sclerosis | |
| Phase 1/2Completed | 15 Aug 2025 | IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy | |
| Phase 1/2Completed | 1 Aug 2026 | Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI | |
| Phase 1/2Completed | 30 Aug 2026 | IC14 for Treatment of Acute Decompensated Heart Failure | |
| Phase 1Completed | 18 Apr 2018 | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026